We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

61 hedge funds and large institutions have $297M invested in PTC Therapeutics in 2013 Q3 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,460% more capital invested

Capital invested by funds: $3.47M → $297M (+$294M)

5,800% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 1

1,933% more funds holding

Funds holding: 3 → 61 (+58)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
61
Holders Change
+58
Holders Change %
+1,933.33%
% of All Funds
1.98%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
59
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BCPEM
Bain Capital Public Equity Management
Massachusetts
+$40.6M
2
CS
Credit Suisse
Switzerland
+$39.2M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$29.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.3M
5
DM
Deerfield Management
New York
+$14.7M

Top Sellers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.93M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$497K
3
ICAP
Independence Capital Asset Partners
Colorado
-$156K
Name Holding Trade Value Shares
Change 		Change in
Stake
VAM
26
Visium Asset Management
New York
$1.09M +$879K +50,600 New
TAM
27
Tocqueville Asset Management
New York
$1.05M +$849K +48,850 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$1.04M +$841K +48,402 New
Northern Trust
29
Northern Trust
Illinois
$953K +$771K +44,386 New
BG
30
BlackRock Group
United Kingdom
$818K +$662K +38,100 New
CCA
31
Catalyst Capital Advisors
New York
$658K +$533K +30,666 New
Deutsche Bank
32
Deutsche Bank
Germany
$643K +$521K +29,998 New
Wells Fargo
33
Wells Fargo
California
$617K +$499K +28,733 New
Goldman Sachs
34
Goldman Sachs
New York
$585K +$474K +27,276 New
BIM
35
BlackRock Investment Management
Delaware
$565K +$457K +26,325 New
Bank of New York Mellon
36
Bank of New York Mellon
New York
$548K +$444K +25,557 New
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
$513K -$1.93M -111,100 -82%
RFC
38
Russell Frank Company
Washington
$513K +$415K +23,900 New
TCIM
39
TIAA CREF Investment Management
New York
$509K +$413K +23,738 New
Charles Schwab
40
Charles Schwab
California
$447K +$347K +19,943 New
GH
41
GAM Holding
Switzerland
$433K +$351K +20,200 New
MWNA
42
Marshall Wace North America
New York
$429K +$348K +20,000 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$296K +$240K +13,800 New
PAM
44
Panagora Asset Management
Massachusetts
$287K +$233K +13,383 New
Nomura Holdings
45
Nomura Holdings
Japan
$262K +$215K +12,379 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$244K +$197K +11,355 New
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$236K +$191K +11,005 New
SIM
48
Spark Investment Management
New York
$226K +$184K +10,600 New
TA
49
Teachers Advisors
New York
$192K +$156K +8,950 New
SG Americas Securities
50
SG Americas Securities
New York
$144K +$116K +6,698 New
1
2
3

PTCT Hedge Fund Activity: Q3 2013 in Review

61 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2013, worth a combined $297M — up 8,460% from $3.47M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new PTCT positions and 1 closed out — a net gain of 58 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Bain Capital Public Equity Management, opening a new position worth an estimated $40.6M. The largest seller was Alyeska Investment Group, cutting an estimated $1.93M.

  • 61 institutional investors held PTC Therapeutics (PTCT) as of Q3 2013, up from 3 in Q2 2013.
  • Funds reported $297M of PTC Therapeutics stock for Q3 2013, up 8,460% quarter-over-quarter.
  • 59 funds opened new PTC Therapeutics positions in Q3 2013 and 1 closed out, a net change of +58 holders.
  • The largest PTC Therapeutics buyer in Q3 2013 was Bain Capital Public Equity Management, an estimated $40.6M added.
  • The largest PTC Therapeutics seller in Q3 2013 was Alyeska Investment Group, an estimated $1.93M sold.

Based on aggregated 13F filings for Q3 2013.